Corcept Therapeutics Inc (CORT)
54.76
-1.67
(-2.96%)
USD |
NASDAQ |
Nov 14, 16:00
54.44
-0.32
(-0.58%)
After-Hours: 20:00
Corcept Therapeutics Research and Development Expense (Quarterly): 59.34M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 59.34M |
| June 30, 2024 | 58.74M |
| March 31, 2024 | 58.50M |
| December 31, 2023 | 54.71M |
| September 30, 2023 | 45.52M |
| June 30, 2023 | 43.28M |
| March 31, 2023 | 40.85M |
| December 31, 2022 | 36.75M |
| September 30, 2022 | 33.29M |
| June 30, 2022 | 32.82M |
| March 31, 2022 | 28.12M |
| December 31, 2021 | 28.52M |
| September 30, 2021 | 28.09M |
| June 30, 2021 | 28.23M |
| March 31, 2021 | 29.02M |
| December 31, 2020 | 28.28M |
| September 30, 2020 | 33.87M |
| June 30, 2020 | 26.50M |
| March 31, 2020 | 26.12M |
| December 31, 2019 | 24.31M |
| September 30, 2019 | 22.80M |
| June 30, 2019 | 21.66M |
| March 31, 2019 | 20.24M |
| December 31, 2018 | 18.79M |
| September 30, 2018 | 18.86M |
| Date | Value |
|---|---|
| June 30, 2018 | 20.54M |
| March 31, 2018 | 17.05M |
| December 31, 2017 | 13.63M |
| September 30, 2017 | 11.69M |
| June 30, 2017 | 7.876M |
| March 31, 2017 | 7.176M |
| December 31, 2016 | 6.484M |
| September 30, 2016 | 7.054M |
| June 30, 2016 | 5.672M |
| March 31, 2016 | 4.634M |
| December 31, 2015 | 4.089M |
| September 30, 2015 | 3.612M |
| June 30, 2015 | 3.341M |
| March 31, 2015 | 4.377M |
| December 31, 2014 | 3.789M |
| September 30, 2014 | 3.047M |
| June 30, 2014 | 4.252M |
| March 31, 2014 | 7.285M |
| December 31, 2013 | 6.567M |
| September 30, 2013 | 5.155M |
| June 30, 2013 | 4.491M |
| March 31, 2013 | 4.257M |
| December 31, 2012 | 4.856M |
| September 30, 2012 | 3.008M |
| June 30, 2012 | 2.668M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
24.31M
Minimum
Dec 2019
59.34M
Maximum
Sep 2024
37.24M
Average
33.06M
Median
Research and Development Expense (Quarterly) Benchmarks
| Catalyst Pharmaceuticals Inc | 3.284M |
| ADMA Biologics Inc | 0.412M |
| Akebia Therapeutics Inc | 7.647M |
| Bioventus Inc | 3.808M |
| Alnylam Pharmaceuticals Inc | 270.93M |